KSI-301 Syringe Preparation and Injection Procedures

Pablo Velazquez-Martin, MD
VP Clinical Research and Translational Medicine

Virtual Investigator Meeting November 2020

KSI-301 & Aflibercept - Handling Differences

KSI-301

- Injection volume: 100 μL
- Dosing mark: 0.1
- Dosing needle: 27G ½ inch needle
- Injection may take 5 seconds due to viscosity of drug

Aflibercept

- Injection volume: 50 µL
- Dosing mark: 0.05
- **Dosing needle:** 30G ½ inch needle

Please note the injection volume difference between KSI-301 and aflibercept. Always ensure the correct volume is prepared and injected!

Pooled Drug Supply – Outside Carton Label


Same study drug kits for BEACON, GLEAM, and GLIMMER!

	Protocol / EudraCT Number:
Lot Number: <blinded lot#=""></blinded>	□ BEACON: KS301P103 / 2020-001061-37
Site Number:	□ GLEAM: KS301P104 / 2020-001062-11 □ GLIMMER: KS301P105 / 2020-001063-82
Subject Number:	— GLIMIMER. NS301F105 / 2020-001063-62
Investigator Name:	Visit Date: Visit Name:
	nl) or Aflibercept 2 mg (40mg/ml) or one Sham vial.
Solution for injection. For intrav	
Directions for use: Refer to Phare	
To be opened by unmasked pers	
Storage Conditions: Store between	
Keep the vial in the outer carton	to protect from light.
	Federal (or United States) law to investigational use
Sponsor: Kodiak Sciences Inc. 2631 H	lanover Street, Palo Alto, CA 94304, USA

KSI-301 Syringe Preparation

Kit Contents:

- KSI-301 vial (red or blue cap)
- BD 1 mL Luer lock syringe
 - Use only a Kodiak supplied BD syringe
- BD 18-gauge x 1 ½ inch 5micron filter needle
- TSK 27-gauge x ½ inch ultrathin wall dosing needle
- Alcohol swab




KSI-301 Key Syringe Preparation tips

- 1. KSI-301 is stored at 2-8°C. Perform all steps at room temperature, it helps with the viscosity.
 - Vial may only be kept at room temperature for up to 8 hours prior to use.
- 2. Firmly attach the needles to the syringe and do not try to readjust. KSI-301 can act as a lubricant causing needle pop-off.
- 3. Always keep the vial upright.
- 4. Be patient! Might take 1 or 2 minutes to draw the medication
- 5. Fill at least 200 microliters (above the 0.2 mL mark)

KSI-301 Syringe PreparationWorking out the bubbles

- Hold the filled 1 mL syringe vertically upright. A noticeable air gap will appear directly above the rubber plunger.
- Remove air bubbles in two smooth down/up movements of the plunger:
 - First, pull the plunger down to 0.8 mL then push it back up to 0.5-0.6 mL until the plunger contacts the drug.
 - Second, repeat the above motion one more time to fully remove the air bubbles.



6. Do not flick the syringe. It is not an effective way to remove air bubbles

KSI-301 Syringe Preparation


- Align the flat top edge of the rubber plunger to the 0.1 mL marking on the syringe barrel.
- The syringe is now ready for intravitreal injection.
- Use within 60 minutes of preparation



KSI-301 Syringe Preparation Video



KSI-301 Syringe Preparation Video



KSI-301 Injection procedure



Ocular Anesthesia

- Unmasked injecting investigator will choose method of anesthesia
- Method chosen must remain constant for duration of trial (including sham injections) to maintain masking

Topical Proparacaine

- Instill 0.5% proparacaine drops to bulbar conjunctival
- Disinfect with 10% povidone iodine
- Apply sterile, cotton-tipped applicator soaked with 0.5% proparacaine to planned injection site for 10 seconds

Subconjunctival Lidocaine

- Instill 0.5% proparacaine drops to bulbar conjunctiva
- Disinfect with 10% povidone iodine
- Draw up 0.2ml of lidocaine into 1-mL syringe using 18-gauge (g) needle.
- Remove 18g with 30g ½-inch needle
- Apply 1 drop 5% povidone iodine and wait 15 sec
- Inject lidocaine into subconjunctival space

Anesthetic gels or viscous formulations are not allowed

Intravitreal Injection Aseptic Technique

- Aseptic conditions using a sterile eyelid speculum and sterile gloves
 - Either surgical masks should be used or minimize speaking during the preparation of the syringe and intravitreal injection
 - If the patient is wearing a face mask, strong consideration should be given to creating a physical barrier between the top of the mask and the eye, to prevent oral flora from traveling out of the top of the mask and contaminating the sterile field. This could be achieved by using a sterile, adhesive eye drape or taping the top of the mask to the skin.
 - Kodiak will be providing 3M Steri-Drapes to all sites upon request!



If you use Steri-Drapes don't forget to use them for both active *and* sham injections

Post-Injection Assessments

To preserve masking, post Injection Assessments should be carried equally for all subjects (including sham injection procedure). **Post-injection Assessments may only be performed by unmasked site staff.**

- Within 5 minutes after the injection, check vision of the study eye for count fingers or hand motion.
- Tonometry (study eye) between 30 and 50 minutes after injection. If the IOP is >30 mmHg or has increased by ≥ 10 mmHg from pre-injection, the IOP will be measured again at 60-80 minutes post-injection. If there are no safety concerns, the subject will be permitted to leave the clinic.
- IOP measurement (either Goldmann tonometry or Tonopen) must remain the same throughout the study for each participant.

Conclusions

- There are two key differences between KSI-301 and aflibercept
 - KSI-301's injecting volume is 100 microliters compared to 50 microliters for aflibercept
 - KSI-301 is more viscous, so drawing the medication and the injection procedure take slightly more time than usual
- Always ensure the correct volume is prepared and injected
- If the patient is wearing a facemask, please create a physical barrier between the top of the mask and the eye.
 - Kodiak will be providing 3M Steri-Drapes to all sites upon request
 - Alternatively, tape the upper edges of the face masks with a medical adhesive tape the top part to the patient's skin

